SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Bristol-Myers Squibb Company

SG&A Efficiency: AstraZeneca vs. Bristol-Myers Squibb

In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, AstraZeneca PLC and Bristol-Myers Squibb Company have demonstrated distinct strategies in managing these costs. From 2014 to 2023, AstraZeneca's SG&A expenses have shown a significant upward trend, peaking in 2022 with a 90% increase from 2016. In contrast, Bristol-Myers Squibb maintained a more stable trajectory, with a notable spike in 2020, reflecting a 53% rise from 2018. This divergence highlights AstraZeneca's aggressive investment in administrative capabilities, while Bristol-Myers Squibb opts for a more conservative approach. As the industry evolves, these strategies will play a pivotal role in shaping their competitive edge. Understanding these trends provides valuable insights into each company's operational focus and market positioning.

Key Insights

• AstraZeneca's SG&A expenses increased by 90% from 2016 to 2022.
• Bristol-Myers Squibb's expenses rose by 53% from 2018 to 2020.
• AstraZeneca's peak in 2022 suggests a strategic shift in administrative investments.